The reality is—scheduling an in-person visit just to increase a beta-blocker dose or add an SGLT2 inhibitor is a waste of time and resources. Cardiologists don’t have the capacity to see patients every 1–2 weeks to uptitrate GDMT, and most health systems lack the infrastructure to do it for them. The result: both clinical inertia and administrative inertia.
That’s why we need new solutions. I’m excited to partner with
@rhythmsci and CEO/founder
@shawnkumar1000 to bring HF-AI to market. HF-AI is a comprehensive heart failure solution that uses home blood pressure readings to remotely titrate guideline-directed therapy. In TURING-HF (JACC: Heart Failure, 2025), cardiologists accepted 90.8% of HF-AI recommendations. It doubled GDMT use, enabled 80% of medication changes remotely, and reduced hospitalizations by 74%.
Building HF-AI was step one. Validating it in a clinical trial was step two. Getting it into the hands of clinicians through RhythmScience is how we change outcomes. By integrating HF-AI into Rhythm360—alongside implantables and home BP data—we can personalize heart failure care at scale.
And ultimately—save lives.
@HanCardiomd @DrMarthaGulati @gcfmd @MKIttlesonMD
RhythmScience is proud to license the groundbreaking HF-AI algorithm from Cedars-Sinai, revolutionizing heart failure care with AI-powered personalized therapy! Clinical validation shows 90.8% cardiologist agreement & 74% fewer hospitalizations. Curious to see how? Let's Discuss!